Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating

Protara Therapeutics (TARA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $23.00 price target.

Andrew Fein has given his Buy rating due to a combination of factors related to Protara Therapeutics’ promising therapeutic candidate, TARA-002. The drug has shown impressive efficacy in the treatment of high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly in patients unresponsive to Bacillus Calmette-Guérin (BCG) therapy. During the Phase II ADVANCED-2 trial, TARA-002 achieved an 80% complete response rate (CRR) at any time and a 100% CRR at six months in patients with carcinoma in situ (CIS), surpassing typical benchmarks.
Furthermore, TARA-002 has demonstrated a favorable safety profile, with no significant treatment-related adverse events reported. The drug’s mechanism of action, which may enhance the immune response post-BCG exposure, adds to its potential effectiveness. Protara’s ongoing trials and future data releases are expected to provide further insights into the drug’s durability and efficacy. These factors collectively support Fein’s positive outlook and Buy rating for Protara Therapeutics’ stock.